1932-8737/asset/CLC_left.gif?v=1&s=bef78ae8a6fe49b573c871234f8b53b4936d2259)
Case Report
Cardiac Amyloidosis Treated with an Implantable Cardioverter Defibrillator and Subcutaneous Array Lead System: Report of a Case and Literature Review
Article first published online: 19 MAY 2009
DOI: 10.1002/clc.20389
Copyright © 2009 Wiley Periodicals, Inc.
1932-8737/asset/cover.gif?v=1&s=aa8daa91991e0fc34c181e4dad93e63f1b1cc6bd "Clinical Cardiology")
Additional Information
How to Cite
Dhoble, A., Khasnis, A., Olomu, A. and Thakur, R. (2009), Cardiac Amyloidosis Treated with an Implantable Cardioverter Defibrillator and Subcutaneous Array Lead System: Report of a Case and Literature Review. Clinical Cardiology, 32: E63–E65. doi: 10.1002/clc.20389
Publication History
- Issue published online: 17 AUG 2009
- Article first published online: 19 MAY 2009
- Manuscript Accepted: 9 DEC 2007
- Manuscript Received: 22 SEP 2007
- Abstract
- References
- Cited By
Abstract
Background
Preventing ventricular arrhythmias in patients with cardiac amyloidosis is challenging since the amyloid protein deposition in the myocardium may interfere with the normal cardiac electric excitation. Most of these patients succumb to either progressive congestive heart failure, or sudden cardiac death (SCD). Implantable Cardioverter Defibrillator (ICD) offers a near sure means of preventing SCD.
Hypothesis
Myocardial infiltration with amyloid results in elevated defibrillation threshold (DFT). Intra-operative strategies may fail to lower DFT during implantation.
Methods
We present a case of a 64-year-old female who had cardiac amyloidosis, and was successfully treated with an ICD and a subcutaneous array lead system.
Conclusion
A subcutaneous array lead system is useful in reducing the DFT, and can terminate ventricular tachycardia or fibrillation by allowing more energy delivery and efficient defibrillation. Copyright © 2009 Wiley Periodicals, Inc.